Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesolv 10 vs Rhinocort Aqua 64 in Grass Pollen Induced Allergic Rhinitis
NCT03755557Phase 3Completed
- Sponsor
- Marinomed Biotech
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesolv in allergic rhinitis (AR) (3 arms), sponsored by Marinomed Biotech. Primary endpoint: Total Nasal Symptom Score. Started Nov 2018; status: completed.
02
Drugs
budesolv
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03755557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755557.